Addressing Unmet Clinical Needs with Radiopharmaceutical Technologies

Blue Earth Diagnostics is committed to transforming the clinical management of patients with cancer in areas of unmet clinical need. We are focused on developing advanced imaging technologies and radiopharmaceuticals, which have potential utility in diagnostic imaging in cancer. These technologies can help physicians detect and locate cancer to make decisions about patient care.

We conduct scientific studies, called clinical trials, to find better ways to identify the location of cancer in the body and understand whether it can be effectively managed. Some of our clinical trials provide information on the benefits, side effects and possible uses for new technologies. Other trials explore new uses for existing imaging technologies. Results from clinical trials are submitted for review to Regulatory Authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory agencies have strict standards for the review of the safety and efficacy of new medicines or new uses of existing medicines. If these standards are achieved, a medicine may be approved and become available by prescription.



PP-UK-0532 / June 2022